Bio-Techne Corporation (TECH)

NASDAQ · Health Care · market cap 8.09B

Share price

$72.41

At the last nightly close

Intrinsic value

$23.71

Range $23.71 – $32.55 — the conservative figure is the low end.

Margin of safety

-67.3%

($23.71 − $72.41) ÷ $72.41

EV / EBIT

71.3

On the median operating profit of 15 fiscal years through 2026.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.

Key metrics

Price / earnings62.4
Price / book5.4
EV / EBITDA34.0
FCF / EV+1.4%
Return on equity+9.0%
Return on assets+6.7%
Debt / equity0.14
Gross margin+66.2%

Market position

52-week high$72.47
52-week low$43.17
From 52-week high-0.1%
RSI (14)62.5
200-day moving average$62.71

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2026-FY1.22B272.6M181.9M1.17263.2M
2025-FY1.22B242.8M73.4M0.47256.6M
2024-FY1.16B246.4M168.1M1.07236.1M
2023-FY1.14B291.0M285.3M1.81216.1M
2022-FY1.11B296.6M272.1M1.66280.4M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedNovember 9, 2026
Consensus EPS estimate0.43

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on TECH.

Run the board on TECH

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.